A clinical trial conducted by Moderna is evaluating an investigational vaccine that may protect people from Epstein-Barr Virus (EBV), which can cause Infectious Mononucleosis, commonly referred to as “mono”. Mono is a common cause of fever, fatigue, sore throat, and enlarged lymph nodes, and can result in prolonged symptoms, like tiredness, as well as hospitalization.
Trial ID: NCT05164094
The Eclipse Trial is evaluating the safety and immune response of an investigational vaccine, called mRNA-1189, that may protect against mono. Participation in the Eclipse Trial lasts approximately 18 months, including a 28-day screening period, a six-month dosing period, and up to 11 months of follow-up observation.
Each year in the United States, there are approximately 500 cases of mono per 100,000 persons. Mono disproportionately affects adolescents and young adults from 15 to 24 years of age. There are currently no approved vaccines to protect against EBV and mono.
We'll check to see if you are eligible by asking you some questions.
Participation in the Eclipse Clinical Trial lasts approximately 18 months and includes phone calls, telemedicine visits, and up to fifteen visits to the study site.
Insurance is not needed to join this clinical trial, and compensation for participants’ time will be available.
In order to participate, participants will need to go to one of the clinical research sites taking part in this clinical trial. Sites are located in:
You will need to travel to one of the study clinics taking part in this clinical trial.
Sites are located in the cities/states identified with the red pin:
We'll check to see if you are eligible by asking you some questions.